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Summary Lymphocyte homing receptor (CD44) is involved in lymphocyte adhesion to endothelial cells of
high endothelial venules (HEVs) and lymphocyte exit from the blood circulation, and it may be involved also
in hematogenous dissemination of malignant lymphoma. Prognostic significance of lymphocyte homing
receptor expression defined by Hermes-3 antibody was studied among 27 gastrointestinal lymphomas followed
up for 8 to 20 years after the diagnosis. Lymphomas lacking or with very weak homing receptor expression
(n = 14, 52%) were associated with 57% 10-year survival rate as compared with only 15% among lymphomas
that expressed CD44 more strongly (P = 0.02). We conclude that lack of lymphocyte homing receptor
expression is common in gastrointestinal lymphoma, and that CD44 expression is associated with
unfavourable prognosis.
Lymphocyte adhesion molecules are involved when the lym-
phocyte adheres to the endothelium in order to exit the blood
circulation. The process of lymphocyte extravasation takes
place in specialised postcapillary high endothelial venules
(HEVs), and several adhesion molecules both on the lym-
phocyte and on the endothelial cell work in concert in the
process (Butcher, 1991). Such molecules on the lymphocyte
are called lymphoctye homing receptors (HRs), and on the
endothelial cell vascular addressins. Human lymphocyte HRs
include L-selectin, which mediates lymphocyte binding to
peripheral lymph nodes (Gallatin et al., 1983), integrins
VLA-4(a4p1) and a4p7, of which the latter appears to be
involved in lymphocyte traffic to mucosal HEVs in the
Peyer's patches (Hu et al., 1992), the cutaneous lymphocyte
antigen (CLA), which is involved in lymphocyte homing to
the skin (Picker et al., 1991), and Hermes/CD44 antigen,
which is involved in lymphocyte binding to peripheral lymph
node, mucosal, and (inflamed) synovial HEVs (Jalkanen et
al., 1987). The leukocyte integrin, LFA-1, probably serves as
an activation-dependent secondary adhesion molecule
involved in strengthening adhesion and diapedesis at many
sites (Hamann et al., 1988; Pals et al., 1988).
Recent evidence suggests that lymphocyte HRs are impor-
tant not only in the trafficking of normal lymphocytes, but
also in dissemination of malignant lymphoma (Bargatze et
al., 1987; Picker et al., 1988; Pals et al., 1989; Jalkanen et al.,
1991). In theory, lymphoma cells that lack adhesion
molecules would not be able to disseminate hematogenously
as efficiently as lymphoma cells that express these molecules,
because HR negative cells do not adhere to the venule
endothelium to exit the blood circulation. Hence, HR
negative lymphomas could form lymphogenic metastases and
their cells could circulate freely in the blood, but such lym-
phomas would be less likely to give rise to hematogenous
metastases. During lymphocyte evolution Hermes/CD44 HRs
are expressed both on early B- and T-cell precursors and on
mature T- and B-cells, but not in the intermediate stages of
lymphocyte differentiation (Horst et al., 1990). In line with
these hypotheses CD44 negative human lymphomas are often
of clinical stage I and are associated with favourable prog-
nosis despite their high histological malignancy grade (Jal-
kanen et al., 1991).
To our knowledge there are currently no data on the
prognostic significance of lymphocyte HR expression in lym-
phomas of the gastrointestinal tract, which is the most com-
mon site for human extralymphatic lymphoma. The present
report on 27 gastrointestinal lymphomas indicates that CD44
expression determined by immunohistochemistry is associated
with poor prognosis.
Materials and methods
Patients
Twenty-seven patients histologically diagnosed with gastro-
intestinal lymphoma and treated in Turku University Central
Hospital between 1973 and 1984 were included in the study.
The patients were found by searching the hospital data files,
and all such patients with both clinical information and
sufficient histological material available were included in the
series. The patient characteristics, treatment, and follow-up
status are shown in Table I. Seventeen (63%) patients were
male, and the median age was 65 years (range, from 30 to 80
years). Eighteen patients had primary gastric lymphoma, and
the rest had the primary tumour either in the duodenum
(n = 1), the jejunum (n = 2), the ileum (n = 3), the colon
(n = 1), or in multiple intestinal sites (n = 2).
Staging was done according to UICC TNM classification
(1987). All patients had laparotomy, but in two cases a
biopsy only was taken without attempting tumour removal.
Patients with lymphoma above the diaphragm and with gas-
trointestinal involvement are included in the series, because
in such cases the origin of lymphoma in the gastrointestinal
tract is often disputable. Stage IV lymphoma was considered
to be present if either another abdominal extralymphatic
organ than the intestine was involved (the pancreas, n = 3;
the liver, n = 3; the uterus, the ovary, the kidney, the dia-
phragm, n = 1 for each), or there was lymphoma in multiple
sites in the gastrointestinal tract (n = 2). Patients have been
followed after diagnosis for a median of 13 years (range, 8 to
20 years, if still living or until death (n = 17). The crude
survival rates at 5 and 10 years after the diagnosis were 57%
and 39%, respectively.
Histology andflow cytometry
Formalin-fixed and paraffin-embedded tissue blocks were sec-
tioned and stained with the Giemsa, hematoxylin and eosin,
periodic acid-Schiff, methyl green and pyronin, and van
Gieson methods. The original histological diagnoses were
reviewed. Subclassification of lymphoma was according to
the modified Kiel classification (Stansfeld et al., 1988), and
classification to MALT (mucosa associated lymphoid tissue)
and non-MALT lymphomas was carried out as by Isaacson
et al. (1984). Hematopoietic origin of lymphomas was
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Table I Clinical, histological, immunohistological and flow sytometric data
Sitea
Stomach, E +
Stomach, E +, N +
Stomach
Stomach, N +
Stomach
Stomach, E +, N +
Ileum, colon, N +
Duodenum
Stomach
Ileum
Stomach, N +
Ileum
Jejunum, N +
Stomach
Jejunum, N +
Stomach, E +
Stomach, N +
Stomach
Stomach, E+, N+
Stomach
Stomach, E +
Stomach
Ileum, N +, colon, E +
Stomach, N +
Ileum, E+, N+
Colon
Stomach, N +
Stage
IVA
IVA
IB
IIB
IA
IVB
IVA
IB
IA
IA
IIA
IA
IIB
IA
IIB
IVA
IIA
IA
IVB
IB
IVA
IA
IVB
IIA
IVB
IB
IA
Histologyb
CB
CB
MALT, LG
MALT, HG
MALT, LG
CB
MALT, HG
MALT, LG
IB
IB
IB
MALT, LG
CB
MALT, LG
IB
MALT, LG
MALT, LG
MALT, LG
MALT, HG
CB
IB
CB
MALT, LG
MALT, LG
LB
CB
IB
S-phase
fraction
(%)
23.7
17.5
11.0
12.0
20.9
?
17.4
18.5
7.6
2.5
21.9
19.3
21.1
I?
15.6
21.4
3.4
16.1
16.8
I?
36.0
29.5
26.3
16.1
25.3
13.6
5.8
CD 44
staining
intensity Treatmentc
-1+ S,CHOP>
-1+ S, RT, CH
-/+ S, COP xI
-/+ S, RT
-1+ 5
-/1+ CHOP x1C
-/1+ S, CHOP>
-/+ S, RT, MC
-/+ S, RT
-/+ S, RT, CO
-/+ S, RT
-/+ S, RT, CO
-1+ 5
-/+ S, RT
++ S, COPx4
+ + S, CHOP>
+ + S, RT, CO
++ S, RT
+ + RT, CHOP
++ S, RT
+ + S, RT, CO
++ S
++ S, COPx2
+++ S, RT, CH
+++ S, RT, CO
+ + + S, RT, CO
+ + + S, RT, CO
IOP x 4
15
K 12
)PP x 9
)P x 6
)Px 15
K5
P x 6
?x 16
P x 21
22
lOP x 1
)p x S
)P x 6
WPx 17
Follow-up
status
Imo, dead
6mo, dead
3yr, dead
5yr, dead
6yr, dead
6yr, dead
8yr, alive
lOyr, alive
1Oyr, alive
12yr, alive
12yr, alive
13yr, alive
14yr, alive
20yr, alive
4mo, dead
9mo, dead
lyr, dead
3yr, dead
3yr, dead
3yr, dead
4yr, dead
5yr, dead
16yr, alive
Imo, dead
7mo, dead
8yr, dead
13yr, alive
aE +, extension of lymphoma to the liver, the pancreas or other intra-abdominal extralymphatic organs other than the bowel; N +,
intra-abdominal lymph node metastases present. bCB, centroblastic; IB, immunoblastic; LB, lymphoblastic; LG, low grade; HG, high grade. CS,
surgery; RT, radiotherapy; COP (cyclophosphamide, vincristine, and prednisone), CHOP contains also doxorubicin.
confirmed with a monoclonal antibody against human leuko-
cyte common antigen (DAKO, Copenhagen, Denmark). All
lymphomas were of B-cell origin (positive with MB2 anti-
body, Clonab, Viereich, Germany, confirmed by antibody
L26, DAKO). The bound primary antibodies were visualised
using the avidin-biotin complex technique (Vector Labora-
tories, Burlingame, CA, USA) with 1,1-diaminobenzidine as
the chromogen. Ten lymphomas were low grade and three
high grade MALT lymphomas, the rest were classified as
centroblastic (n = 7), immunoblastic (n = 6) or lymphoblastic
(n = 1) lymphoma.
Flow cytometry was done with a FACStar Flow
Cytometer (Becton-Dickinson Immunocytometry Systems,
Mountain View, CA) from deparaffinised tissue (Hedley et
al., 1983). DNA was stained with propidium iodide. For each
histogram 20,000 particles were analysed. The median
coefficient of variation (CV) of diploid peaks was 4.5%.
S-phase fraction (SPF) was calculated with the rectangular
method (Camplejohn et al., 1989). All histograms were inter-
pretable for DNA ploidy, but SPF was not assessed in three
cases either due to overlapping stemlines (n = 1) or presence
of excessive cell debris (n = 2).
Staining ofCD44 and LFA-J
CD44 expression was determined using Hermes-3 MoAb as
serum free culture supernatant. The production and
specificity of Hermes-3 have been described elsewhere (Jal-
kanen et al., 1987). It recognises a common determinant of
CD44 class of HRs mediating lymphocyte binding to
peripheral lymph node, mucosal, and synovial HEVs.
Expression of CD44 was scored as -/ + (negative or very
weak staining of tumour cells), + + (intermediate intensity),
or + + + (strong staining intensity comparable to that of
tumour infiltrating lymphocytes). Staining intensity was
scored independently by two readers (S.J. and P.K.), and in
the few cases with discordant classification a consensus was
sought. A variable number of tumour infiltrating lym-
phocytes was seen in all cases, easily recognisable with the
MTI antibody (Clonab, Viereich, Germany). Since all stained
intensely with Hermes-3, these served as a useful internal
standard for staining intensity analysis.
A mouse MoAb (a generous gift from Prof. C. Gahmberg,
University of Helsinki) against the beta-subunit (CD18) of
the CDT 1/CD18 adhesion protein complex was used to deter-
mine expression of LFA-T beta chain. Expression of LFA-1
beta was considered positive if more than 10% of tumour
cells showed surface staining. LFA-1 determination was not
done in one case due to lack of tissue. Anti-CD18 and
Hermes-3 give comparable staining patterns on fresh frozen
sections and paraffin-embedded tissue sections (Jalkanen et
al., 1990).
Coding
The patients were provided with a numerical code, and
CD44/LFA-1 beta analyses, histologic classification, and SPF
were done without knowledge of survival or other clinical
information. These determinations were also done without
knowledge of the results of the other analyses.
Statistical analyses
Survival analysis was done using a BMDP computer pro-
gram (BMDP Statistical Software, Department of
Biomathematics, University of California Press, Los Angeles,
CA). Crude survival was estimated with the product-limit
method, and comparison of survival between groups was
done using the log-rank test (BMDP IL). Frequency tables
were analysed using the chi-square test or Fisher's exact test.
The SPF distributions between weak and strong HR staining
intensity groups were compared using Mann-Whitney's U-
test. All P-values are 2-tailed.
Results
Fourteen (52%) lymphomas were either negative or very
weakly positive with Hermes antibody (HR -/+), nine
(33%) showed moderate staining intensity (HR + +), and
Case
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
Sexl
Age
F/53
M/30
M/66
M/76
M/80
M/40
M/66
M/63
M/63
M/53
M/53
F/50
M/61
F/53
M/73
M/36
F/65
M/80
M/48
F/65
F/75
F/76
F/66
M/70
F/66
F/73
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four (15%) were brightly positive (HR + + +, Figures 1-3).
Fourteen of the 26 lymphomas with successful staining for
LFA-1 beta were negative and 12 (46%) were positive.
Lymphomas with negative or very weakly positive CD44
expression were associated with more favourable survival
than those with more positive CD44 expression (Figure 4).
Only 15% of the patients with moderate or strong CD44
expression were alive 10 years after the diagnosis as com-
pared with 57% if lymphoma cells did not express CD44
(P = 0.02). Of the other factors tested, patients with stage I
lymphoma had better prognosis than those with stage II or
IV lymphoma in a univariate analysis (P = 0.04), whereas
DNA ploidy (diploid, n = 16, vs nondiploid, n = 11,
P= 0.25), SPF (,median, 17%, vs >median, P= 0.42),
presence of B-symptoms (P = 0.34), histological classification
(MALT vs non-MALT, or low grade MALT lymphomas vs
the rest, P = 0.37 and 0.30, respectively), sex (P = 0.69), or
LFA-1 expression (P = 0.71) did not have significant associa-
tion with survival. No significant association between CD44
expression (-/+ vs + + or +++) could be found with
sex, stage (I vs II or IV), DNA ploidy, SPF, LFA-l beta
expression, histological classification (MALT vs non-MALT,
or low grade MALT lymphomas vs the rest), or the primary
site (the stomach vs other, P>0.1 for all comparisons).
Discussion
Lack of CD44 expression was associated with favourable
outcome in gastrointestinal lymphoma in the present series.
Figure 1 Immunoblastic lymphoma with strong positive staining intensity (+ + +) for Hermes-3/CD44 in the lymphoma cells. A
gastric gland in the upper left is unstained. The bar in the lower right corner is 75gm.
Figure 2 Centroblastic type of gastric lymphoma with intermediate (+ +) positive staining intensity for CD44 in the lymphoma
cells. The bar is 75gm.CD44 EXPRESSION IN LYMPHOMA 431
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Figure 3 MALT lymphoma of low grade ofmalignancy with negative (+/-) staining for CD44 in the lymphoma cells. The bar is
75gm.
Because CD44 expression was significantly associated neither
with a large SPF, which is associated with aggressive histo-
logical features and poor outcome in lymphoma (Rehn et al.,
1990; Joensuu et al., 1991), nor with high histological grade
of malignancy, the result suggests that the poor outcome of
CD44 positive gastrointestinal lymphomas may be due to
their greater tendency to give rise to distant metastases.
Although a multivariate analysis was not carried out due to
the limited size of the series, in addition to CD44 expression
only postsurgical stage showed some association with sur-
vival among the several factors studied, which suggests that
lymphocyte CD44 expression may be one of the strongest
prognostic factors in gastrointestinal lymphoma.
Fourteen (52%) of the gastrointestinal lymphomas did not
express CD44. In a recent series consisting of 245 non-
Hodgkin lymphomas investigated by us by similar methods
(Jalkanen et al., 1991) only 77 (31%) lymphomas were CD44
negative or expressed it weakly (P = 0.03), suggesting that
gastrointestinal lymphomas may have a smaller tendency to
100-
90-
80- u - mHR -/+ (n = 14)
_6- 57%
50 l
HR ++/+++ (n = 13)
cl)
disseminate hematogenously than non-Hodgkin lymphoma in
general. In accordance with this, gastrointestinal lymphoma
may apparently occasionally be cured by local therapy, such
as surgery alone (Dragosics et al., 1985).
Several homing-associated molecules work in concert in
lymphocyte extravasation. Therefore, a better correlation
with survival might be obtained if a panel of these molecules
were investigated, but analysis of most of such molecules is
probably not possible from formalin fixed tissue. Lympho-
cyte adhesion molecule a4P7 is likely to be involved in lym-
phocyte homing to Peyer's patches and the appendix (Hu et
al., 1992). Although little is known about lymphocyte hom-
ing receptors involved in the recruitment of immunoblasts or
memory lymphocyte populations to the intestinal lamina pro-
pria, venules in the intestinal lamina propria express the
mucosal vascular addressin, which appears to play an impor-
tant role in recruiting gut-homing lymphocyte populations
from the blood to this site. However, gut intraepithelial
leukocytes and many lamina propria lymphocytes express the
mucosal lymphocyte antigen (MLA), defined by MoAbs
HML1 or Ber ACT8 in the human, which may play a role in
lymphocyte homing to the gut (Picker & Butcher, 1992).
It is concluded that gastrointestinal lymphoma with absent
or very weak CD44 expression is associated with more
favourable prognosis than lymphoma with stronger CD44
expression. Larger series now need to be studied in order to
investigate further the relationship between CD44 expression
and different histopathological subtypes of gastrointestinal
lymphoma, and between CD44 expression and other known
prognostic factors in this disease. Studies performed from
fresh lymphoma tissue where multiple homing-associated
molecules are simultaneously evaluated are also highly war-
ranted.
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Figure 4 Survival of 27 patients with gastrointestinal Uymphoma
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